With Spirojatamol showing the highest binding energy scores against PS1 (−6.9 kcal/mol), molecular docking confirmed the activity of this metabolite against AD targets PS1 and Spirojatamol formed a stable complex at 100 nanoseconds, according to additional investigation using MD simulations. This evidence concerns the gene PSEN1 and Alzheimer disease.